{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:01:02Z","timestamp":1780394462841,"version":"3.54.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Cancer-associated venous thromboembolism (CAVTE) is a preventable, life-threatening complication with a considerable morbidity and mortality. Primary venous thromboembolism (VTE) prophylaxis is currently recommended; however, the health and economic benefits have not been evaluated and compared in China. This study aimed to assess and compare the cost-effectiveness of anticoagulants in primary CAVTE prevention among cancer patients in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model with a 5-year horizon was established to evaluate the costs and effectiveness of direct oral anticoagulants (DOACs) compared to low-molecular-weight heparins (LMWHs) and no prevention in primary prophylaxis of CAVTE in China. Key clinical outcomes were obtained from the available clinical trials, comparing DOACs (rivaroxaban and apixaban) with LMWHs or with no thromboprophylaxis. Utility and the cost inputs were all obtained from the published literature or local data with public sources. The total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were estimated as the main endpoints of the modal for each strategy. The assessment of uncertainty was performed involving deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA). Impact of time horizon, generic drug price, and individual DOACs were assessed in scenario and subgroup analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Primary prophylaxis using DOACs were projected to yield 1.866 QALYs at a cost of $3,287.893, resulting in the ICERs of $12,895.851 (DOACs vs. no-thromboprophylaxis) and $43,613.184\/QALYs (LMWHs vs. DOACs). Sensitivity analysis revealed that ICER was sensitive to the VTE and bleeding risk, drug cost of anticoagulants, self-payment ratio, and overall death rate of cancer. Probabilistic sensitivity analysis showed that DOACs and LMWHs had a 48% and 45% probability of being cost-effective at a 5-year time horizon, respectively. When the time horizon extended to 10 years, DOACs achieved a cost-effective probability of 43%. Among individual DOACs, apixaban was found to be the preferred strategy in VTE prevention due to its incremental health gain with an acceptable cost increase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Primary thromboprophylaxis with DOACs was cost-effective in cancer patients at a willing-to-pay (WTP) threshold of $37,125.24\/QALY in China. Cancer death rate, risk of VTE and major bleeding, and the drug cost assumed greater relevance and importance in the decision-making process for primary thromboprophylaxis in cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1373333","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:36:37Z","timestamp":1727066197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Yue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TianChen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuiLin","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/s1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/1871529x1502151209110620","article-title":"Use of new oral anticoagulants in the treatment of venous thromboembolism and thrombotic prophylaxis","volume":"15","author":"Akin","year":"2015","journal-title":"Cardiovasc Hematol. Disord. Drug Targets"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2147\/vhrm.S271411","article-title":"Direct oral anticoagulants for the prevention and acute treatment of cancer-associated thrombosis","volume":"18","author":"Attard","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"B6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/th16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e43447","DOI":"10.7759\/cureus.43447","article-title":"Comparative efficacy of oral apixaban and subcutaneous low molecular weight heparins in the treatment of cancer-associated thromboembolism: a meta-analysis","volume":"15","author":"Baloch","year":"2023","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B10","first-page":"2787","article-title":"Cost-effectiveness study of rivaroxaban in the prevention of venous thromboembolism after total knee replacement","volume":"22","author":"Chen","year":"2011","journal-title":"China Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e039057","DOI":"10.1136\/bmjopen-2020-039057","article-title":"Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism","volume":"10","author":"de Jong","year":"2020","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"Cd008500","DOI":"10.1002\/14651858.CD008500.pub4","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-020-00926-2","article-title":"New oral anticoagulants for thromboprophylaxis in patients with cancer receiving chemotherapy: an economic evaluation in a Chinese setting","volume":"40","author":"Du","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/s1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/atvbaha.123.318779","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/13696998.2017.1331912","article-title":"Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in The Netherlands","volume":"20","author":"Heisen","year":"2017","journal-title":"J. Med. Econ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1200\/jco.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4070\/kcj.2017.0328","article-title":"Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer","volume":"48","author":"Kim","year":"2018","journal-title":"Korean Circ. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1182\/blood-2019-127286","article-title":"Cost-utility analysis of apixaban compared to usual care for the primary thromboprophylaxis of ambulatory cancer patients initiating chemotherapy","volume":"134","author":"Kimpton","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1200\/jco.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"Klerk","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.clinthera.2016.01.020","article-title":"Cost-effectiveness of apixaban versus other oral anticoagulants for the initial treatment of venous thromboembolism and prevention of recurrence","volume":"38","author":"Lanitis","year":"2016","journal-title":"Clin. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/jco.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2045894018791358","DOI":"10.1177\/2045894018791358","article-title":"Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England","volume":"8","author":"Martinez","year":"2018","journal-title":"Pulm. Circ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1801220","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1253\/circj.CJ-20-1247","article-title":"Mortality, recurrent thromboembolism and major bleeding in cancer-associated and non-cancer pulmonary embolism patients treated with direct oral anticoagulants","volume":"88","author":"Nakano","year":"2021","journal-title":"Circ. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/circulationaha.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.medcli.2022.06.022","article-title":"Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a systematic review and Bayesian network meta-analysis","volume":"160","author":"Ning","year":"2023","journal-title":"Med. Clin. Barc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.3390\/jcm10204648","article-title":"Direct oral anticoagulant therapy for isolated distal deep vein thrombosis associated with cancer in routine clinical practice","volume":"10","author":"Ogino","year":"2021","journal-title":"J. Clin. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/strokeaha.116.012945","article-title":"Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage","volume":"47","author":"Ottosen","year":"2016","journal-title":"Stroke"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/jco.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B42","doi-asserted-by":"publisher","first-page":"Cd008500","DOI":"10.1002\/14651858.CD008500.pub4","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Rutjes","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40261-022-01217-8","article-title":"Cost-utility analysis comparing direct oral anticoagulant and low molecular weight heparin therapies for secondary prevention of cancer-associated thrombosis","volume":"42","author":"Shin","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B45","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4065\/81.6.758","article-title":"Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial","volume":"81","author":"Sideras","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8559","DOI":"10.1007\/s00520-022-07235-8","article-title":"Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)","volume":"30","author":"Tsoukalas","year":"2022","journal-title":"Support Care Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/blood.v122.21.580.580","article-title":"Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE","volume":"122","author":"Vadhanraj","year":"2013","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1200\/jco.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3781\/j.issn.1000-7431.2005.03.015","article-title":"Clinical study of anticoagulant combination with chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"25","author":"Wang","year":"2005","journal-title":"Tumor"},{"key":"B53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12959-021-00319-1","article-title":"Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis","volume":"19","author":"Wumaier","year":"2021","journal-title":"Thromb. J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e038433","DOI":"10.1136\/bmjopen-2020-038433","article-title":"Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China","volume":"10","author":"Yang","year":"2020","journal-title":"BMJ Open"},{"key":"B55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J. Natl. Cancer Cent"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3969\/j.issn.1009-6663.2013.11.067","article-title":"Clinical research on low molecular heparin in the prevention of venous thromboembolism of patients with lung cancer received chemotherapy","volume":"18","author":"Zhang","year":"2013","journal-title":"J. Clin. Pulm. Med."},{"key":"B57","first-page":"378","article-title":"Clinical study of low molecular weight heparin combined with chemotherapy in the treatment of advanced gastric cancer","volume":"23","author":"Zhu","year":"2014","journal-title":"Mod. J. Integr. Traditional Chin. West. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/bjh.12163","article-title":"Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)","volume":"160","author":"Zwicker","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1373333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:36:42Z","timestamp":1727066202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1373333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":58,"alternative-id":["10.3389\/fphar.2024.1373333"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1373333","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1373333"}}